Porcine Reproductive and Respiratory Syndrome (PRRS)

Porcine Reproductive and Respiratory Syndrome represents one of the most economically devastating viral diseases affecting the global swine industry. First identified in North America in 1987 and subsequently in Europe in 1990, PRRS has become endemic in most major swine-producing regions worldwide. The disease is caused by PRRS virus (PRRSV), an RNA virus belonging to the family Arteriviridae that primarily targets cells of the monocyte and macrophage lineage. This tropism for immune cells underlies both the clinical manifestations of the disease and its profound impact on pig health and production efficiency.

The clinical presentation of PRRS varies dramatically depending on the age and reproductive status of affected pigs, the virulence of the specific virus strain, and the immune status of the herd. In breeding herds, the disease characteristically causes reproductive failure including late-term abortions, increased stillbirths, mummified fetuses, and the birth of weak piglets with poor survival rates. Growing pigs develop respiratory disease ranging from mild to severe pneumonia, often complicated by secondary bacterial infections. The immunosuppressive effects of PRRSV infection increase susceptibility to opportunistic pathogens and contribute to the porcine respiratory disease complex.

The economic impact of PRRS on the swine industry is staggering, with annual losses in the United States alone estimated at approximately $664 million. These losses result from reproductive failure in breeding herds, increased nursery and finishing mortality, reduced growth rates, decreased feed efficiency, and elevated medication costs for controlling secondary infections. Beyond direct disease costs, PRRS control programs require substantial investments in diagnostics, vaccination, and management changes that further impact production economics. The persistent nature of infection and viral genetic diversity create ongoing challenges for disease elimination.

Understanding PRRS is essential for anyone involved in swine production, as the disease influences virtually every aspect of modern pig farming. While no cure exists for PRRSV infection, comprehensive management programs combining biosecurity, strategic vaccination, and herd health monitoring can effectively control clinical disease and minimize economic losses. The development of improved vaccines and diagnostic tools continues to advance control capabilities, though the virus's genetic plasticity and ability to evade immune responses ensure that PRRS will remain a significant challenge for the foreseeable future.

PRRS virus serves as the sole causative agent of porcine reproductive and respiratory syndrome, though its biological characteristics make it a particularly challenging pathogen to control. PRRSV is an enveloped, single-stranded RNA virus with a genome approximately 15 kilobases in length. Two major genotypes exist: Type 1 (European origin) and Type 2 (North American origin), with significant genetic diversity within each genotype. This genetic variability results from the high mutation rate characteristic of RNA viruses and from recombination events between different strains, producing a constantly evolving viral population that complicates vaccine development and diagnostic interpretation.

Viral transmission occurs through multiple routes, creating numerous opportunities for pathogen spread between pigs and herds. Direct contact with infected pigs represents the primary transmission mechanism, with the virus present in respiratory secretions, saliva, urine, feces, semen, and mammary secretions. Aerosol transmission can occur over short distances within facilities and, under certain environmental conditions, over distances of several kilometers between farms. Contaminated fomites including vehicles, equipment, boots, and clothing can mechanically transfer the virus. Semen from infected boars efficiently transmits PRRSV, making artificial insemination a significant risk factor for introducing infection into naive herds.

The pathogenesis of PRRSV infection centers on the virus's tropism for cells of the monocyte and macrophage lineage, particularly porcine alveolar macrophages that serve as critical components of respiratory immune defenses. Upon entering the host, the virus initially replicates in regional lymphoid tissue before spreading systemically through viremia. Infection of alveolar macrophages impairs their phagocytic and immunoregulatory functions, compromising the pig's ability to clear both the primary viral infection and secondary bacterial pathogens. This immunosuppressive effect contributes substantially to the clinical manifestations of PRRS and explains the frequent occurrence of secondary bacterial infections.

Host factors influencing disease severity include age, immune status, and genetic background. Fetuses in the last trimester of gestation are highly susceptible to transplacental infection, leading to reproductive failure and the birth of congenitally infected piglets. Young pigs with waning maternal antibodies experience heightened susceptibility to clinical disease. Certain pig genetic lines appear to show differential susceptibility to PRRSV infection, though the genetic basis for this variation is not fully characterized. Concurrent infections with other pathogens including porcine circovirus type 2, swine influenza virus, and Mycoplasma hyopneumoniae exacerbate disease severity through synergistic interactions.

Environmental and management factors significantly influence the epidemiology of PRRS within and between herds. Continuous flow production systems allow ongoing viral transmission between age groups, maintaining endemic infection. Inadequate biosecurity permits repeated introductions of new viral strains. Stress from overcrowding, poor ventilation, temperature extremes, and transportation increases viral shedding and disease susceptibility. The persistence of PRRSV in recovered pigs, which may shed virus intermittently for weeks to months after clinical recovery, complicates elimination efforts and maintains viral circulation within affected populations.

Early warning signs of PRRS often appear subtle and nonspecific, particularly in herds with endemic infection where clinical manifestations may be mild. In breeding herds, the earliest indicator frequently involves slight increases in sow feed refusal or reduced reproductive performance that may go unnoticed without careful record analysis. Nursery caretakers may observe slightly reduced feed disappearance, marginally increased mortality, or a few more pigs showing signs of respiratory distress than usual. These incremental changes often precede more dramatic clinical outbreaks, making vigilant monitoring and trending of production parameters essential for early detection.

Reproductive manifestations dominate the clinical picture in breeding herds experiencing acute PRRS outbreaks. Late-term abortions occurring in the last third of gestation represent the most dramatic sign, with abortion rates potentially reaching 30 percent or higher during severe outbreaks. Affected sows may deliver litters containing mixtures of stillborn piglets, mummified fetuses at various stages of development, and weak liveborn piglets. These weak piglets often display splay leg, respiratory distress, and poor nursing behavior, resulting in high preweaning mortality rates. Sows may show anorexia, mild fever, and lethargy coinciding with reproductive losses, though some exhibit minimal clinical signs despite aborting.

Respiratory disease characterizes PRRS in growing pigs, with severity varying based on viral strain virulence and concurrent infections. Affected pigs develop increased respiratory rate and effort, with labored abdominal breathing visible when observing groups from a distance. Coughing and sneezing occur frequently, and secondary bacterial pneumonia produces purulent nasal discharge. The blue discoloration of ears, snout, and vulva that gives the disease its alternative name blue ear disease results from cyanosis associated with respiratory compromise and occurs in severe cases. Weight loss and rough hair coat reflect the catabolic state associated with chronic infection.

Behavioral changes accompanying PRRS infection include reduced activity, decreased competitive ability at feeders, and huddling or piling behavior suggesting chilling. Affected pigs often segregate from penmates and show reduced responsiveness to human approach or handling. Feed and water consumption decline, contributing to dehydration and weight loss. Neurological signs occasionally occur in severe cases, with incoordination, trembling, and paralysis reported. The generalized malaise reflects both direct viral effects and the inflammatory response to infection.

Physical examination findings vary with the stage and severity of infection. Temperature elevation to 103-106°F (39.4-41.1°C) occurs during acute viremia but may normalize as infection progresses to chronic stages. Auscultation of affected pigs often reveals abnormal lung sounds including crackles, wheezes, and areas of consolidation. Lymph nodes may be enlarged and palpable, particularly the submandibular and inguinal nodes. Conjunctivitis with ocular discharge and periocular edema gives some pigs a characteristic swollen appearance around the eyes. Skin discoloration ranging from erythema to cyanosis may be visible on the ears, abdomen, and extremities.

Emergency symptoms requiring immediate veterinary attention include respiratory distress severe enough to cause open-mouth breathing or cyanosis, sudden abortion storms affecting multiple sows, widespread mortality in nursery populations, and the appearance of highly virulent strain characteristics such as high fever, severe hemorrhagic lesions, and rapid death. Highly pathogenic PRRSV strains, which have emerged particularly in Asia, can cause devastating outbreaks with mortality rates exceeding 50 percent in some populations. Any sudden deterioration in herd health parameters warrants immediate investigation to differentiate PRRS from other diseases and implement appropriate response measures.

Clinical examination and herd history provide initial diagnostic direction for PRRS, though laboratory confirmation is essential given the nonspecific nature of many clinical signs. The combination of reproductive failure in breeding stock with respiratory disease in nursery and finishing pigs strongly suggests PRRS involvement. Review of production records may reveal declining conception rates, increased returns to estrus, elevated stillborn rates, and rising nursery mortality weeks or months before acute clinical outbreaks become apparent. Mortality patterns and clinical sign distribution within age groups help differentiate PRRS from other differential diagnoses.

Laboratory diagnosis of PRRS relies primarily on detection of viral nucleic acid or antigen, viral isolation, and serological testing. Polymerase chain reaction testing has become the gold standard for PRRSV detection due to its sensitivity, specificity, and rapid turnaround time. Appropriate samples include serum, lung tissue, lymph nodes, and oral fluid collected using cotton ropes hung in pens. Oral fluid testing has revolutionized population-level surveillance by providing a non-invasive method for monitoring large groups of pigs. Viral isolation in cell culture provides definitive identification and allows characterization of isolates, though it requires more time and specialized laboratory capabilities.

Serological testing detects antibodies against PRRSV and provides information about exposure history rather than current infection status. Enzyme-linked immunosorbent assay remains the most widely used serological platform, with commercial tests detecting antibodies to both Type 1 and Type 2 virus. Antibodies typically become detectable 7 to 14 days post-infection and may persist for months to years. Interpreting serological results requires understanding that positive results indicate exposure but not necessarily current infection, while negative results in the face of clinical disease may reflect testing before seroconversion. Sequencing of viral isolates provides genetic information useful for epidemiological investigations and vaccine strain matching.

Differential diagnosis for PRRS encompasses multiple conditions depending on the predominant clinical presentation. Reproductive failure must be differentiated from other causes of abortion and stillbirth including parvovirus, leptospirosis, Aujeszky's disease, classical swine fever, and noninfectious causes. Respiratory disease in growing pigs shares features with swine influenza, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, and other bacterial and viral pneumonias. The porcine respiratory disease complex frequently involves multiple pathogens acting synergistically, making comprehensive diagnostic panels advisable. Herd-level investigation typically involves testing multiple animals across age groups, necropsy of representative cases, and ongoing surveillance to characterize disease dynamics.

Direct treatment of PRRSV infection remains limited by the lack of effective antiviral therapies against this pathogen, making management strategies focus on supportive care and control of secondary complications. No medications effectively eliminate or suppress PRRSV replication in infected pigs, distinguishing it from bacterial diseases where antimicrobial therapy can target the causative organism. Treatment efforts instead concentrate on maintaining pig comfort, supporting immune function, and preventing or treating the secondary bacterial infections that contribute substantially to clinical disease severity and mortality.

Antimicrobial therapy targeting secondary bacterial pathogens represents the primary medical intervention for pigs with PRRS-associated respiratory disease. Selection of appropriate antibiotics should consider the bacterial flora present in the specific herd, ideally guided by culture and sensitivity testing from diagnostic submissions. Common secondary pathogens requiring treatment include Pasteurella multocida, Streptococcus suis, Haemophilus parasuis, and Actinobacillus pleuropneumoniae. Broad-spectrum injectable antibiotics provide initial coverage for acutely ill pigs, with water or feed medication extending treatment to larger populations. Withdrawal times must be observed for all antimicrobials used in food-producing animals.

Supportive care measures address the systemic effects of infection and enhance the pig's ability to recover. Anti-inflammatory drugs including meloxicam and flunixin meglumine help control fever, reduce pain and inflammation, and improve appetite and activity levels. Ensuring adequate hydration through easy water access becomes particularly important for febrile and anorexic pigs. Hospital pen management separates affected individuals for closer monitoring and protects them from competition with healthier penmates. Temperature management prevents chilling in debilitated animals, with supplemental heat sources providing comfort for young or severely affected pigs.

Vaccination strategies form a cornerstone of PRRS management, though vaccines do not treat existing infections and their efficacy varies depending on the match between vaccine and field virus strains. Modified live virus vaccines provide broader cross-protection but carry theoretical risks of viral recombination and vaccine virus transmission. Killed virus vaccines offer improved safety but typically provide narrower protection and require booster doses. Strategic vaccination programs may target breeding animals to reduce reproductive losses, piglets to decrease nursery mortality, or entire populations to reduce viral circulation. Vaccine selection and timing should be tailored to specific herd situations with veterinary guidance.

Herd-level treatment decisions extend beyond individual pig therapy to encompass population management strategies during outbreaks. Mass medication of affected groups addresses secondary bacterial infections across the population at risk. Intentional exposure programs may be considered for naive herds facing certain outbreak situations, aiming to achieve uniform infection and recovery before critical production stages. Such strategies carry risks and require careful veterinary supervision. The decision framework for managing PRRS outbreaks must balance immediate clinical needs against long-term control objectives and economic realities.

Economic considerations heavily influence treatment intensity and duration in commercial swine operations facing PRRS. The substantial costs of medication, labor, and reduced performance must be weighed against expected benefits of treatment. Pigs with severe disease and poor prognosis may warrant euthanasia rather than prolonged treatment attempts. Herd-level cost-benefit analysis helps producers determine appropriate investment levels in outbreak response versus acceptance of short-term losses while implementing longer-term control strategies. Veterinary consultation helps navigate these complex decisions balancing animal welfare, regulatory compliance, and economic sustainability.

Recovery timelines for pigs surviving PRRS vary substantially based on disease severity, viral strain characteristics, and the presence of complicating secondary infections. Pigs with mild to moderate respiratory involvement typically show clinical improvement within one to two weeks of symptom onset, though subclinical effects may persist longer. Growth rates often remain suppressed for weeks to months following recovery, reflecting the metabolic costs of immune response and tissue repair. Complete restoration of normal growth performance may never occur in severely affected pigs, resulting in permanent productive losses.

Post-acute monitoring focuses on identifying pigs that fail to thrive despite apparent clinical recovery and assessing population-level performance trends. Individual pigs may develop chronic poor-doing syndrome characterized by rough hair coat, reduced growth, and ongoing susceptibility to secondary infections. Respiratory function may remain compromised by lung damage sustained during acute disease, manifested as exercise intolerance and increased respiratory effort during handling. Regular weighing and comparison against expected growth curves reveals the extent of PRRS impact on production efficiency.

Viral persistence in recovered pigs creates ongoing epidemiological challenges for herd management. PRRSV may be shed intermittently for weeks to months following clinical recovery, with individual variation in shedding duration. This prolonged shedding maintains viral circulation within populations and complicates elimination strategies. Immunological recovery progresses over weeks, with neutralizing antibody responses developing that provide partial protection against reinfection with related strains. However, the genetic diversity of PRRSV means that immunity to one strain may provide limited protection against antigenically distinct variants.

Return to production considerations must account for the persistent impacts of PRRS on performance and the ongoing risk of viral shedding. Growing pigs recovered from PRRS frequently require extended finishing periods to reach market weights, with economic calculations determining whether continued feeding is profitable. Breeding stock that experienced reproductive failure during outbreaks may return to normal fertility following recovery, though evaluation of subsequent litter performance is advisable before retaining affected animals. Boars recovered from PRRS may shed virus in semen for extended periods, necessitating testing before returning to breeding service.

Vaccination programs serve as a primary prevention tool for PRRS in herds where the virus is already present or where introduction risk is high. Current vaccines include both modified live virus products and killed virus preparations, each with distinct advantages and limitations. Modified live vaccines replicate in the host and stimulate broader immune responses, providing better cross-protection against heterologous field strains. Killed vaccines avoid risks associated with live virus but typically require more frequent boosters and provide narrower protection. Vaccine selection, timing, and target populations should be determined through consultation with veterinarians familiar with the specific herd situation and regional PRRS epidemiology.

Biosecurity measures form the foundation of PRRS prevention, particularly for herds attempting to remain negative or to prevent introduction of new strains into infected herds. Physical isolation through adequate distances from neighboring pig operations reduces aerosol transmission risk, with air filtration providing additional protection for high-value herds in dense pig production areas. Strict entry controls limit human and equipment traffic into facilities, with mandatory shower-in policies, dedicated clothing and footwear, and extended downtime requirements for personnel who have visited other pig operations. Vehicle wash stations and controlled entry points prevent contamination from transport equipment.

Gilt and semen introduction protocols represent critical control points for preventing PRRS entry through replacement breeding stock. Purchasing negative breeding stock from documented negative sources and maintaining extended quarantine with testing before entry into the main herd reduces introduction risk. Acclimation protocols for incoming gilts in positive herds aim to achieve infection, recovery, and development of immunity before breeding, preventing acute disease during gestation. Semen testing and sourcing from negative boar studs or studs using risk mitigation procedures protects against venereal transmission.

Management practices that reduce viral transmission within positive herds help stabilize infection and minimize clinical impact. McREBEL procedures, standing for Management Changes to Reduce Exposure to Bacteria to Eliminate Losses, aim to reduce pathogen spread from older infected pigs to younger susceptible animals. These practices include strict all-in-all-out pig flow, prohibition of cross-fostering after initial processing, prohibition of moving pigs backwards in the production flow, and elimination of routine processing procedures that could transfer pathogens between litters.

Regional control and elimination initiatives have demonstrated success in reducing PRRS prevalence across geographic areas. Area regional control programs coordinate biosecurity and vaccination strategies among neighboring producers to reduce overall viral circulation. Herd elimination strategies including whole-herd depopulation and repopulation, test-and-removal, load-close-expose protocols, and herd closure with internal exposure and rollover have successfully produced PRRS-negative herds from positive populations. These intensive control programs require substantial investment and commitment but offer the prospect of freedom from ongoing PRRS-related losses.

Daily management practices in PRRS-affected herds prioritize early disease detection, consistent environmental conditions, and minimization of stress factors that exacerbate clinical expression. Caretakers should systematically observe all pigs during each barn walk, noting respiratory signs, activity levels, body condition, and any abnormalities requiring attention. Mortality recording with brief notation of clinical signs provides valuable trending data for identifying emerging problems. Temperature and ventilation monitoring ensures consistent environmental conditions that support pig comfort and immune function.

Housing and environmental management significantly influence PRRS clinical expression and the success of control programs. Ventilation systems should maintain air quality while minimizing drafts and temperature fluctuations that stress pigs. Adequate space allowances reduce social stress and limit respiratory pathogen transmission between closely housed animals. Strict separation between age groups prevents transmission from older carrier pigs to younger susceptible animals. Thorough cleaning and extended drying times between groups reduce environmental viral load, though PRRSV survives poorly in dry conditions compared to many other swine pathogens.

Herd health program integration ensures that PRRS management coordinates with control of other significant diseases. The porcine respiratory disease complex involves multiple pathogens acting synergistically, making comprehensive respiratory disease control essential. Vaccination programs addressing Mycoplasma hyopneumoniae, swine influenza, and PCV2 complement PRRS vaccines in reducing overall respiratory disease burden. Diagnostic monitoring should include ongoing PRRS surveillance alongside testing for other pathogens, with interpretation considering the interactions between concurrent infections.

Record systems supporting PRRS management track both production parameters and health indicators. Weekly or biweekly pig inventory with mortality recording allows calculation of mortality rates by site, room, and age group. Reproduction records including conception rates, farrowing rates, litter sizes, and stillborn percentages reveal PRRS impacts on breeding herd performance. Growth data including average daily gain, feed conversion, and days to market weight documents growing pig impacts. Diagnostic submission tracking maintains history of laboratory findings including PRRS PCR and sequencing results.

Economic analysis guides investment decisions in PRRS management programs and helps producers understand the true cost of disease. Comprehensive cost accounting should include direct losses from mortality and reduced performance, treatment and vaccination expenses, biosecurity investment, and labor costs associated with enhanced management protocols. Comparison of costs between control strategy options helps identify the most economically efficient approach for specific situations. Return on investment calculations for elimination programs compare upfront costs against projected long-term savings from disease freedom. Economic modeling tools developed by universities and extension services can assist with these analyses.

Susceptibility to PRRS virus infection appears to be essentially universal among domestic pig breeds, with no breeds demonstrating complete resistance to infection. However, research has identified differences in disease tolerance and severity among genetic lines, suggesting that host genetics influence outcomes following infection. Studies comparing responses of different breed crosses have found variation in viral load, duration of viremia, lung pathology scores, and weight gain depression following experimental challenge. These findings have stimulated interest in identifying genetic markers associated with PRRS tolerance that could be incorporated into breeding programs.

Production system characteristics influence PRRS risk independently of genetic factors, with intensive confinement operations facing different challenges than extensive or outdoor production systems. Large breeding operations with frequent introduction of replacement gilts face ongoing exposure risk through genetic supply chains. Multi-site production systems with pig movement between premises create opportunities for viral spread that single-site operations avoid. High-health and genetic nucleus herds maintaining PRRS-negative status face catastrophic consequences if biosecurity failures occur, making their risk profile different from commercial operations managing endemic infection.

Genetic selection programs are beginning to incorporate PRRS-related traits, though this remains an emerging area. Genomic research has identified quantitative trait loci associated with viral load and weight gain following PRRS challenge, with markers on pig chromosome 4 showing particularly strong associations. Selection for general disease resilience and improved survival rates may indirectly enhance PRRS outcomes by favoring pigs with more robust immune function. Commercial breeding companies increasingly track health performance data from multiplication and commercial herds, creating opportunities to incorporate disease-related outcomes into selection indices. As genomic tools become more sophisticated and cost-effective, selection for PRRS tolerance may become a practical component of genetic improvement programs.

The porcine respiratory disease complex represents the constellation of conditions most closely related to PRRS, reflecting the synergistic interactions between multiple respiratory pathogens. Swine influenza virus infection shares many clinical features with PRRS respiratory disease and frequently occurs concurrently, with co-infection producing more severe outcomes than either pathogen alone. Mycoplasma hyopneumoniae causes chronic respiratory disease that predisposes pigs to secondary bacterial pneumonias and interacts with PRRSV to enhance overall respiratory disease severity. Understanding these relationships guides integrated respiratory disease control programs.

Porcine circovirus type 2 associated diseases interact significantly with PRRS due to their shared impacts on immune function. Both PRRSV and PCV2 affect cells of the monocyte and macrophage lineage, creating compounded immunosuppression when co-infection occurs. The combination frequently results in porcine circovirus associated disease expression including postweaning multisystemic wasting syndrome. Vaccination against both pathogens has become standard practice in most commercial operations, with protocols designed to address their interactive effects on pig health and performance.

Secondary bacterial infections commonly accompany PRRS and contribute substantially to clinical disease manifestations and economic losses. Streptococcus suis frequently causes meningitis, arthritis, and septicemia in PRRS-affected pigs, with the immunosuppression from viral infection enabling bacterial invasion. Haemophilus parasuis causing Glasser's disease similarly exploits compromised respiratory defenses. Pasteurella multocida and Actinobacillus pleuropneumoniae cause bacterial pneumonia that compounds viral respiratory damage. Effective PRRS management requires concurrent attention to these secondary pathogens through appropriate antimicrobial stewardship and vaccination programs.